Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation.
Saved in:
| Title: | Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation. |
|---|---|
| Authors: | Fuchs SNR; Department of Developmental Biology, Erasmus Medical Center, Rotterdam, the Netherlands.; Oncode Institute, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Stalmann USA; Department of Developmental Biology, Erasmus Medical Center, Rotterdam, the Netherlands.; Oncode Institute, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Snoeren IAM; Department of Developmental Biology, Erasmus Medical Center, Rotterdam, the Netherlands.; Oncode Institute, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Bindels E; Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Schmitz S; Department of Developmental Biology, Erasmus Medical Center, Rotterdam, the Netherlands.; Oncode Institute, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Banjanin B; Department of Developmental Biology, Erasmus Medical Center, Rotterdam, the Netherlands.; Oncode Institute, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Hoogenboezem RM; Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., van Herk S; Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Saad M; Department of Cell and Tumor Biology, Faculty of Medicine, Rheinisch-Westfälische Technische Hochschule Aachen University, Aachen, Germany., Walter W; MLL Munich Leukemia Laboratory, Munich, Germany., Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany., Seillier L; Cancer Research Center Cologne Essen, University Hospital Cologne, Cologne, Germany.; Joint Research Center for Computational Biomedicine, University Hospital Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany., Saez-Rodriguez J; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany., Dugourd AJF; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany., Lehmann KV; Cancer Research Center Cologne Essen, University Hospital Cologne, Cologne, Germany.; Joint Research Center for Computational Biomedicine, University Hospital Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany., Ben-Neriah Y; The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel., Gleitz HFE; Department of Developmental Biology, Erasmus Medical Center, Rotterdam, the Netherlands.; Oncode Institute, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands., Schneider RK; Department of Developmental Biology, Erasmus Medical Center, Rotterdam, the Netherlands.; Oncode Institute, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.; Department of Cell and Tumor Biology, Faculty of Medicine, Rheinisch-Westfälische Technische Hochschule Aachen University, Aachen, Germany. |
| Source: | Blood advances [Blood Adv] 2024 Feb 13; Vol. 8 (3), pp. 766-779. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
